"Toll-Like Receptor 7" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pattern recognition receptor that binds several forms of imidazo-quinoline including the antiviral compound Imiquimod.
| Descriptor ID |
D051199
|
| MeSH Number(s) |
D12.776.543.750.705.910.500.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Toll-Like Receptor 7".
Below are MeSH descriptors whose meaning is more specific than "Toll-Like Receptor 7".
This graph shows the total number of publications written about "Toll-Like Receptor 7" by people in this website by year, and whether "Toll-Like Receptor 7" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2009 | 3 | 0 | 3 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 2 | 2 | 4 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Toll-Like Receptor 7" by people in Profiles.
-
Mature microRNA-binding protein QKI suppresses extracellular microRNA let-7b release. J Cell Sci. 2024 Nov 01; 137(21).
-
TLR7 promotes smoke-induced experimental lung damage through the activity of mast cell tryptase. Nat Commun. 2023 Nov 14; 14(1):7349.
-
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. Cancer Immunol Res. 2022 12 02; 10(12):1441-1461.
-
Regulation and function of Id2 in plasmacytoid dendritic cells. Mol Immunol. 2022 08; 148:6-17.
-
B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Front Immunol. 2022; 13:794684.
-
TLR7 gain-of-function genetic variation causes human lupus. Nature. 2022 05; 605(7909):349-356.
-
Costimulation of ?dTCR and TLR7/8 promotes Vd2 T-cell antitumor activity by modulating mTOR pathway and APC function. J Immunother Cancer. 2021 12; 9(12).
-
Systematic Optimization of Potent and Orally Bioavailable Purine Scaffold as a Dual Inhibitor of Toll-Like Receptors 7 and 9. J Med Chem. 2021 07 08; 64(13):9279-9301.
-
Discovery of Self-Assembling Small Molecules as Vaccine Adjuvants. Angew Chem Int Ed Engl. 2021 01 11; 60(2):961-969.
-
A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist. J Med Chem. 2020 05 14; 63(9):4776-4789.